Liver Transplantation Clinical Trial
Official title:
Short and Long-term Outcomes After Transplantation With Hyper-reduced Liver Grafts in Low-Weight Pediatric Recipients
NCT number | NCT03594864 |
Other study ID # | 321654 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 21, 2018 |
Est. completion date | June 3, 2018 |
Verified date | July 2018 |
Source | Hospital Italiano de Buenos Aires |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The shortage of organs has always been a problem in pediatric liver transplants due to the lack of donors with an adequate size. Different techniques of hepatic reduction have been described that allow to use larger organs in the pediatric population. However, in these techniques the maximum reduction achieved by segments 2 and 3 is excessive for low-weight children. Since 1997 the liver transplantation group at Hospital Italiano de Buenos Aires has developed and practiced a technique called hepatic hyper-reduction, which consists in reducing the lateral segment of a living donor, adapting the shape and size of the graft to the needs of the recipient. The investigators have performed approximately 50 pediatric liver transplants with live donors in low weight children in whom the hyper-reduction technique has been applied. The aim of the present study is to describe postoperative morbidity and mortality and analyze overall and graft survival.
Status | Completed |
Enrollment | 58 |
Est. completion date | June 3, 2018 |
Est. primary completion date | June 3, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Months to 17 Years |
Eligibility |
Inclusion Criteria: - < or = 17 years old. - Having undergone live donor liver transplantation. - Having received hyper-reduced liver grafts - At the Liver Transplantation Unit of the Hospital Italiano de Buenos Aires - Between June 1997 and April 2018 Exclusion Criteria: - > 17 years old. - Cadaveric liver transplant - Whole liver grafts. |
Country | Name | City | State |
---|---|---|---|
Argentina | Hospital Italiano de Buenos Aires | Capital Federal |
Lead Sponsor | Collaborator |
---|---|
Hospital Italiano de Buenos Aires |
Argentina,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival at 1 year. | Overall survival was defined as the time from surgery to death (all causes) or date of last follow-up, measured in months. | Overall survival wil be reported at 1 year after liver transplantation. | |
Primary | Overall survival at 3 years. | Overall survival was defined as the time from surgery to death (all causes) or date of last follow-up, measured in months. | Overall survival wil be reported at 3 years after liver transplantation. | |
Primary | Overall survival at 10 years. | Overall survival was defined as the time from surgery to death (all causes) or date of last follow-up, measured in months. | Overall survival wil be reported at 10 years after liver transplantation. | |
Primary | Graft survival at 1 year. | Graft survival was defined as the time from surgery to the date of re-transplantation or re-entry to waiting list, measured in months. | Graft survival wil be reported at 1 year after liver transplantation. | |
Primary | Graft survival at 3 years. | Graft survival was defined as the time from surgery to the date of re-transplantation or re-entry to waiting list, measured in months. | Graft survival wil be reported at 3 years after liver transplantation. | |
Primary | Graft survival at 10 years. | Graft survival was defined as the time from surgery to the date of re-transplantation or re-entry to waiting list, measured in months. | Graft survival wil be reported at 10 years after liver transplantation. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
Withdrawn |
NCT00167492 -
Enteric Coated Myfortic for Liver Transplant Recipients
|
Phase 4 | |
Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 |